Manlhiot, Cedric <br/><br/>
Safety of intravenous immunoglobulin in the treatment of juvenile dermatomyositis: adverse reactions are associated with immunoglobulin A content.  [electronic resource] 

 -  Pediatrics  Mar 2008 
 - e626-30 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1098-4275 
<br/><br/><label>Standard No.: </label>10.1542/peds.2007-1218  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Ambulatory Care<br/>Child<br/>Child, Preschool<br/>Cohort Studies<br/>Dermatomyositis--diagnosis<br/>Dose-Response Relationship, Drug<br/>Drug Administration Schedule<br/>Female<br/>Follow-Up Studies<br/>Hospitals, Pediatric<br/>Humans<br/>Immunoglobulin A--metabolism<br/>Immunoglobulins, Intravenous--administration & dosage<br/>Logistic Models<br/>Male<br/>Maximum Tolerated Dose<br/>Multivariate Analysis<br/>Ontario<br/>Probability<br/>Retrospective Studies<br/>Risk Assessment<br/>Severity of Illness Index<br/>Treatment Outcome